Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
On June 23, 2025, the Food and Drug Administration conferred accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or...
Tafasitamab-cxix is approved by the USFDA for relapsed or refractory follicular lymphoma
On June 18, 2025, the US FDA approved tafasitamab‑cxix (Monjuvi), in combination with lenalidomide and rituximab, for adults with relapsed or refractory follicular lymphoma. The inMIND trial...
PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity,...
Breakthrough Treatments for Advanced Breast Cancer in 2025
In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic...
Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
On June 12, 2025, the FDA approved pembrolizumab for both neoadjuvant and adjuvant use in adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC),...
Mitomycin intravesical solution is approved by the USFDA for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
On June 12, 2025, the FDA approved mitomycin intravesical solution (brand name Zusduri, formerly UGN‑102) as the first non‑surgical, chemoablative treatment for recurrent low‑grade, intermediate‑risk non‑muscle‑invasive bladder...
Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
On June 11, 2025, the FDA approved taletrectinib (brand name Ibtrozi) for adults with locally advanced or metastatic ROS1‑positive non‑small cell lung cancer. Decision was...
Darolutamide is approved by the USFDA for metastatic castration-sensitive prostate cancer
On June 3, 2025, the FDA approved darolutamide (brand name Nubeqa) for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC), with or...
Atezolizumab Plus Chemotherapy Improves Survival in Advanced-Stage Small-Cell Lung Cancer: Insights from the IMpower133 Study
The IMpower133 study highlights a breakthrough in treating extensive-stage small-cell lung cancer (ES-SCLC). Adding atezolizumab, a PD-L1 inhibitor, to standard chemotherapy significantly improved overall and...
Satri-cel CAR T-Cell Therapy: A New Era in Gastric Cancer Treatment
Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, has shown promise in treating advanced gastric and gastroesophageal junction cancers. In a phase II trial, it significantly improved...
Shanghai Pulmonary Hospital’s Breakthrough Treatment Offers New Hope for Global Lung Cancer Patients
Shanghai Pulmonary Hospital has introduced a groundbreaking lung cancer treatment that is offering renewed hope to patients worldwide. With advanced therapeutic approaches and pioneering clinical...
Advancing Alström Syndrome Treatment in China: Gene Therapy and Clinical Innovations at NCMC, Shanghai
Alström Syndrome is a rare genetic disorder with no current cure, but emerging gene therapies in China offer new hope. At NCMC, Shanghai, cutting-edge research...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.